Antibe Announces Results of 2022 Annual Meeting

Rhea-AI Summary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) held its annual meeting of shareholders, where all resolutions were approved. Key points included the election of directors, with Robert E. Hoffman receiving 89.12% support, and Roderick Flower achieving 94.91%. The company aims to develop safer therapies targeting inflammation, focusing on its lead drug, otenaproxesul, as an alternative to opioids. Voting results are available on SEDAR.

Antibe's pipeline also includes ATB-352, targeting specialized pain, and future goals include developing treatments for inflammatory bowel disease.

Positive

• All resolutions at the annual meeting were approved, indicating strong shareholder support.
• Directors were elected with high approval percentages, showcasing confidence in company leadership.
• Antibe's focus on developing safer anti-inflammatory therapies addresses significant market needs.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:

Director Nominee	Outcome	% For	% Withheld
Robert E. Hoffman	Elected	89.12%	10.88%
Roderick Flower	Elected	94.91%	5.09%
Amal Khouri	Elected	93.51%	6.49%
Dan Legault	Elected	90.14%	9.86%
Walt Macnee	Elected	93.91%	6.09%
Jennifer McNealey	Elected	93.67%	6.33%
John L. Wallace	Elected	94.31%	5.69%
Yung Wu	Elected	94.22%	5.78%

Voting results on all matters voted on at the Meeting have been filed on SEDAR.

About Antibe Therapeutics Inc.
Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s anticipated next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005529/en/

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-577-1443

christina@antibethera.com

Source: Antibe Therapeutics Inc.

FAQ

What were the results of Antibe Therapeutics annual meeting of shareholders?

All resolutions were approved, and the directors were elected with significant support percentages.

What is the significance of the board elections for ATBPF?

The election of directors with high approval ratings reflects strong shareholder confidence in the company's leadership.

What is Antibe Therapeutics' lead drug?

Antibe's lead drug is otenaproxesul, which is being developed as a safer alternative to opioids and NSAIDs.

What future developments can investors expect from Antibe Therapeutics?

Antibe plans to target inflammatory bowel disease with its future drug development efforts.